APA

Krausz S., Boumans M. J. H., Gerlag D. M., Lufkin J., van Kuijk A. W. R., Bakker A., de Boer M., Lodde B. M., Reedquist K. A., Jacobson E. W., O'Meara M. & Tak P. P. (20120813). Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. : Arthritis and rheumatism.

Chicago

Krausz Sarah, Boumans Maria J H, Gerlag Danielle M, Lufkin Joelle, van Kuijk Arno W R, Bakker Alian, de Boer Maarten, Lodde Beatrijs M, Reedquist Kris A, Jacobson Eric W, O'Meara Michael and Tak Paul P. 20120813. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. : Arthritis and rheumatism.

Harvard

Krausz S., Boumans M. J. H., Gerlag D. M., Lufkin J., van Kuijk A. W. R., Bakker A., de Boer M., Lodde B. M., Reedquist K. A., Jacobson E. W., O'Meara M. and Tak P. P. (20120813). Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. : Arthritis and rheumatism.

MLA

Krausz Sarah, Boumans Maria J H, Gerlag Danielle M, Lufkin Joelle, van Kuijk Arno W R, Bakker Alian, de Boer Maarten, Lodde Beatrijs M, Reedquist Kris A, Jacobson Eric W, O'Meara Michael and Tak Paul P. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. : Arthritis and rheumatism. 20120813.